The voltage‐gated potassium channel Kv1.3 is also receiving attention as a therapeutic target for obesity, in addition to potential therapeutic capabilities for neuroinflammatory diseases. Here, KCNA3 is linked to obesity due to melanocortin 4 receptor deficiency.